KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Taxes (2016 - 2020)

Historic Change in Taxes for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Q3 2020 value amounting to -$25.1 million.

  • Supernus Pharmaceuticals' Change in Taxes fell 126842.35% to -$25.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.9 million, marking a year-over-year decrease of 3171.58%. This contributed to the annual value of -$9.9 million for FY2019, which is 17896.66% down from last year.
  • Supernus Pharmaceuticals' Change in Taxes amounted to -$25.1 million in Q3 2020, which was down 126842.35% from $15.9 million recorded in Q2 2020.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Taxes peaked at $15.9 million during Q2 2020, and registered a low of -$25.1 million during Q3 2020.
  • For the 5-year period, Supernus Pharmaceuticals' Change in Taxes averaged around -$5000.0, with its median value being $782000.0 (2016).
  • In the last 5 years, Supernus Pharmaceuticals' Change in Taxes surged by 748181.82% in 2017 and then crashed by 2417611.94% in 2018.
  • Supernus Pharmaceuticals' Change in Taxes (Quarter) stood at -$804000.0 in 2016, then skyrocketed by 1275.25% to $9.4 million in 2017, then plummeted by 59.48% to $3.8 million in 2018, then tumbled by 162.03% to -$2.4 million in 2019, then crashed by 954.78% to -$25.1 million in 2020.
  • Its Change in Taxes was -$25.1 million in Q3 2020, compared to $15.9 million in Q2 2020 and $6.7 million in Q1 2020.